

**IN THE UNITED STATES PATENT AND TRADEMARK OFFICE**

APPLICANTS: Verheijen *et al.*  
SERIAL NUMBER: 10/576,861 EXAMINER : Solola, Taofiq A.  
FILING DATE: February 2, 2007 ART UNIT : 1625  
FOR: CARBAMOYL ESTERS THAT INHIBIT CHOLINESTERASE AND  
RELEASE PHARMACOLOGICALLY ACTIVE AGENTS

Commissioner for Patents  
P.O. Box 1450  
Alexandria, VA 22313-1450

**SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT**

Pursuant to the duty of disclosure under 37 C.F.R. §§1.56, 1.97 and 1.98, Applicants hereby makes of record the documents listed on the attached Form PTO-1449, as well as copies of the listed documents.

This Information Disclosure Statement is being filed after the mailing date of the first Office Action, but before the mailing date of either a final action under 37 C.F.R. §1.113 or a Notice of Allowance under 37 C.F.R. §1.311. The fee of \$180.00 as set forth in 37 C.F.R. §1.17(p) is paid herewith.

The items of information contained in this Information Disclosure statement were first cited in the corresponding International Search Report for the related Application No. PCT/US2008/008773.

In accordance with 37 CFR 1.98(a)(2)(ii), Applicants have not submitted copies of U.S. patents and U.S. patent applications. Applicants submit herewith copies of foreign patents and non-patent literature in accordance with 37 CFR 1.98(a)(2).

It is respectfully requested that the Examiner consider completely the cited information, along with any other information, in reaching a determination concerning the patentability of the present claims, and sign the enclosed form PTO-1449 to evidence that the cited information has

APPLICANTS: Verheijen *et al.*  
U.S.S.N.: 10/576,861


been fully considered by the Patent and Trademark Office during the examination of this application.

By submitting this Information Disclosure Statement, the Applicants make no representation that: (1) a search has been performed, of the extent of any search performed, or that more relevant information does not exist; (2) the information cited in the Statement is, or is considered to be, material to patentability as defined in 37 C.F.R. §1.56(b); and (3) the information cited in the Statement is, or is considered to be, in fact, prior art as defined by 35 U.S.C. §102.

Notwithstanding any statements by the Applicants, the Examiner is urged to form his/her own conclusion regarding the relevance of the cited information. An early and favorable action is hereby requested.

Please charge any fees that may be due, or credit any overpayment of same, to Deposit Account No. 50-0311, Attorney Reference No. 34251-501NATL.

Respectfully submitted,



Ivor R. Elmf, Reg. No. 39,529  
Heidi A. Erlacher, Reg. No. 45,409  
Jennifer L. Loebach, Reg. No. 57,977  
Attorneys/Agents for Applicants  
MINTZ, LEVIN, COHN, FERRIS,  
GLOVSKY and POPEO, P.C.

Address all written correspondence to

**Customer No.: 30623**

Tel: (617) 542-6000

Fax: (617) 542-2241

Dated: March 1, 2010

4847987v.1